我们的技术：应用领域

2003年我们推出了Port-a-Patch全自动膜片钳，是一款易学易用的的膜片钳系统。此后我们推出了许多产品，包括在Port-a-Patch成功的经验上提高通量与实验灵活性的设备。现在，我们提供中等、高通量的全自动膜片钳设备、自动脂双层记录设备。基于SSM的电生理设备、阻抗与场电位记录设备。这些设备广泛应用于: 离子通道研究、转运体与孔蛋白记录与筛选研究、高通量、安全与毒理研究。我们将持续听取客户意见发展我们的技术来满足研究与药物研发的需求。

药物研发

加速药物研发

Nanion's products are used in all aspects of drug screening and safety testing because of the unprecedented experimental flexibility coupled with increased throughput.

The whole portfolio from the smallest patch clamp rig in the world "Port-a-Patch" to the automated patch clamp instrument with the highest throughput "SyncroPatch 384/768PE" are valuable for applications in target identification, efficacy, safety, SAR studies and HTS:

Drug Discovery

科学研究

大学和研究机构:
我们一起创造新的想法，开辟新的研究领域

As a spin-off from the Ludwig-Maximillian University, Munich, and with a workforce composed of 20% with PhD, we understand the needs of academic researchers. Over the years, we have been involved in more than twenty collaborative grant applications and EU projects including dynamic clamp, temperature sensitivity, mechanosensitivity, optogenetics and zero gravity, amongst others.

Through collaborations with academic groups, we are inspired to pursue new discoveries and ideas. Many collaborations have paved the way for technical solutions. We highly value our academic network and contacts at Universities and Research Institutes.

"在太空中"的Port-a-Patch

Porty in space

iPSC分化的细胞

诱导多能干细胞:新领域的曙光

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult human cells (e.g. blood cells or fibroblasts). The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize in Physiology or Medicine along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent." Pluripotent stem cells hold great promise in the field of drug discovery and regenerative medicine. Because they give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a source of human cells previously not available to the pharmaceutical industry. These differentiated cells derived from iPS cells, also called iPSC-derived cells are nowadays used for cardiac safety assays (iPSC-derived cardiomyocytes), hepatotox assays (iPSC-derived hepatocytes), neurotox and drug discovery for neuronal diseases such as Alzheimer's and Parkinson disease (iPSC-derived neurons).

Cor.4U

Cor.4U: Microscopical image of iPSC-derived cardiomyocytes (image was kindly provided by NCardia)

在Nanion设备上使用iPSC分化细胞试验

We have long-lasting collaborations with well-known iPSC-derived cell providers and together, we have developed new features and new instruments to provide our customers with solutions for human iPSC-derived cell assays.

Icon CE CardioExcyte 96: A device which records action potentials (EFR) and contraction motility (impedance) of iPSC-derived cardiomyocytes in parallel. It is used for cardiac safety studies. The CardioExcyte 96 SOL was developed to pace channelrhodopsin-transfected iPSC-derived cardiomyocytes with light.

Patchliner: The automated patch clamp instrument measures the action postentials of iPSC-derived neurons and cardiomyocytes in current clamp mode. A specific feature was implemented, the "Minimized Cell Consumption", specifically for the usage of iPSC-derived cells and primary cells.

SyncroPatch 384/768PE: The automated patch clamp instrument measures the action postentials of iPSC-derived neurons and cardiomyocytes in current clamp mode.

心脏安全

心脏安全: 新药研发的主要障碍

The first appearance of the term ‘safety pharmacology’ in the published literature dates back to 1980. The term was certainly in common usage in the 1980s within the pharmaceutical industry to describe nonclinical pharmacological evaluation of unintended effects of candidate drugs for regulatory submissions. Back then it was part of a wider ‘general pharmacology’ assessment, which addressed actions of a drug candidate beyond the therapeutically-intended effects. The only detailed guidelines indicating the requirements from drug regulatory authorities for general pharmacology studies were from the Ministry of Health, Labour, and Welfare. Nowadays, the term ‘general pharmacology’ is no longer used, and the ICH S7A guidelines distinguish between primary pharmacodynamics (“studies on the mode of action and/or effects of a substance in relation to its desired therapeutic target”), secondary pharmacodynamics (“studies on the mode of action and/or effects of a substance not related to its desired therapeutic target”) and safety pharmacology (“studies that investigate the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above.”)

Preclinical safety pharmacology integrates in silico, in vitro and in vivo approaches. In vitro safety pharmacology studies are focused on early hazard identification and subsequent compound profiling in order to guide preclinical in vivo safety and toxicity studies. Early compound profiling can flag for receptor-, enzyme-, transporter-, and ion channel-related liabilities of NCEs (e.g., inhibition of the human ether-a-go-go related gene protein (hERG)). The ICH7B gregulatory guidance document defines the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals.

CiPA: Comprehensive in vitro Proarrhythmia Assay (2013): In the coming years, the FDA plans to update the current regulatory documents for preclinical and clinical safety evaluation of proarrhythmic risk in humans (i.e. ICH-S7B and ICH-E14). The Comprehensive in vitro Proarrhythmia Assay (CiPA) is a novel safety pharmacology paradigm intending to provide a more accurate assessment of cardiac safety testing for potential proarrhythmic events in humans. This initiative is driven by a steering team including partners from US FDA, HESI, CSRC, SPS, EMA, Health Canada, Japan NIHS and PMDA. The CiPA initiative includes in vitro assays coupled with in silico reconstructions of cellular cardiac electrophysiological activity with verification of relevance through comparison of drug effects in human stem cell-derived cardiomyocytes. If these evaluation efforts succeed, CiPA will become a Safety Pharmacology screening tool for drug research and development purposes. The CiPA Steering Committee and the ICH-S7B and ICH-E14 Working Groups will position the CiPA paradigm within the upcoming revisions of the aforementioned regulatory documents

(Source: Wikipedia "Safety Pharmacology")

心脏离子通道

(Image Source: The-Crankshaft Publishing)

心脏离子通道的数据、应用与文献

药物靶点：离子通道

离子通道: 除GPCR和激酶外最重要的药物研发靶点

疼痛

Pain is a complex disease which can progress into a debilitating condition. One therapeutic avenue, the modulation of ion channel signaling by small molecules, has shown the potential to treat pain. In the following section please find a selection of ion channels which are important drug targets for pain:

自身免疫病

Pharmacological targeting of ion channels has long been recognized as an attractive strategy for the treatment of autoimmune diseases. A severe autoimmune disorder of the central nervous system is Multiple sclerosis (MS). A multitude of different cell types are involved in the complex pathophysiology of this inflammation disorder, including cells of the immune system (e.g. T and B lymphocytes and microglia), the neurovascular unit (e.g. endothelial cells and astrocytes) and the central nervous system (e.g. astrocytes and neurons). In the following section please find a selection of ion channels which are important drug targets for autoimmune diseases as MS:

通道病

通道病:干扰离子通道功能

长QT间期综合症

Long QT syndrome (LQTS) is a rare congenital and inherited or acquired heart condition in which delayed repolarization of the heart following a heartbeat increases the risk of episodes of Torsades de Pointes (TdP, a form of irregular heartbeat that originates from the ventricles). These episodes may lead to fainting and sudden death due to ventricular fibrillation. Episodes may be provoked by various stimuli, depending on the subtype of the condition. Several channelopathies cause different QT-Syndromes. In the following section please find a selection of ion channels which are involved:

囊胞性纤维症

Cystic fibrosis (CF) is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. Long-term issues include difficulty breathing and coughing up mucus as a result of frequent lung infections. CF is inherited in an autosomal recessive manner. It is caused by the presence of mutations in both copies of the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A number of small molecules that aim at compensating various mutations of the CFTR gene are under development. Go to the CFTR page here:

CFTR - Cystic Fibrosis Transmembrane Conductance Regulator - ATP-Binding Cassette Sub-family C Member 7